Dr. Andrew D. Schiermeier Ph.D. serves as Chief Operating Officer, Executive Vice President of the Company. Prior to his current role, Dr. Schiermeier served as our executive vice president of corporate strategy and development since October 2018, as our executive vice president, corporate strategy from April 2018 through October 2018 and as our senior vice president, eXtellia, an Intellia division that focused on ex vivo research and development, from January 2017 through April 2018. Dr. Schiermeier has over two decades of experience as an executive in the biotechnology and pharmaceutical sectors, with experience ranging from managing operations for startups to directing the strategic expansion of global brands. From March 2013 through June 2016, Dr. Schiermeier served as senior vice president, head of oncology and general manager of the Merck-Pfizer Immuno-Oncology Alliance at Merck KGaA. From June 2016 to December 2016, Dr. Schiermeier served as an independent consultant to multiple pharmaceutical and biotechnology companies, including Verastem, Inc., Kynan Duke Pharma, LLP and Intellia. Dr. Schiermeier served as the chief operating officer of Aura Biosciences, Inc. from January 2011 through May 2013. From January 2012 through May 2013, Dr. Schiermeier was a corporate advisor to Pathogenica, Inc. Dr. Schiermeier served as the chief executive officer of Lantibio, Inc., from February 2007 through February 2008. Dr. Schiermeier served in chairman and chief executive officer roles from November 2007 through December 2014 at Medicine in Need Corp, an international not-for-profit, non-governmental organization aimed at liberating burdened populations from diseases of poverty through advanced drug and vaccine delivery. Dr. Schiermeier earned a Ph.D. in engineering and applied mathematics from Harvard University, an M.S. in bio-mechanical engineering from Stanford University and an international M.B.A. from College des Ingenieurs in Paris, France.
What is Andrew Schiermeier's net worth?
The estimated net worth of Andrew Schiermeier is at least $42,640.00 as of March 6th, 2019. Schiermeier owns 3,250 shares of Intellia Therapeutics stock worth more than $42,640 as of November 21st. This net worth approximation does not reflect any other investments that Schiermeier may own. Learn More about Andrew Schiermeier's net worth.
How do I contact Andrew Schiermeier?
Has Andrew Schiermeier been buying or selling shares of Intellia Therapeutics?
Andrew Schiermeier has not been actively trading shares of Intellia Therapeutics in the last ninety days. Most recently, Andrew Schiermeier sold 1,377 shares of the business's stock in a transaction on Tuesday, January 5th. The shares were sold at an average price of $55.86, for a transaction totalling $76,919.22. Learn More on Andrew Schiermeier's trading history.
Who are Intellia Therapeutics' active insiders?
Are insiders buying or selling shares of Intellia Therapeutics?
In the last year, insiders at the sold shares 7 times. They sold a total of 37,420 shares worth more than $1,085,489.31. The most recent insider tranaction occured on October, 2nd when CAO Michael P Dube sold 2,012 shares worth more than $38,248.12. Insiders at Intellia Therapeutics own 3.2% of the company.
Learn More about insider trades at Intellia Therapeutics. Information on this page was last updated on 10/2/2024.
